Cell Therapy News/Articles, page-1442

So Pluristem have reported there small compassionate results from work in Israel. Their next step is to apply for initiation of a multinational regulated clinical trial
program for the potential use of PLX cells in the treatment of patients suffering from
complications associated with COVID-19.

In this regard, while Pluristem expects to continue treating patients for complications associated with COVID-19 under the compassionate use program in Israel, Pluristem does not intend to provide further updates on the status of this
program and rather update on the status and progress of its contemplated clinical trial program.

Meanwhile Mesoblast has hit the ground running with a phase 3 completed product with a cleared FDA application for 240 patient radmomized multi-centre trial in the US.

Early reports are the remestemcel trial results are very encouraging and we should be excited and the SP has responded accordingly. There is huge upside still to come especially when you consider expanded aplications across our pipeline.

Sit tight, I know I am...